Tandem Diabetes, Solventum, LeMaitre, UFP Technologies, and Artivion Stocks Trade Down, What You Need To Know

What Happened?

A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada. The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions.

Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks.

Among others, the following stocks were impacted:

• Healthcare Technology for Patients company Tandem Diabetes (NASDAQ:TNDM) fell 3.3%. Is now the time to buy Tandem Diabetes? Access our full analysis report here, it’s free.

• Surgical Equipment & Consumables - Diversified company Solventum (NYSE:SOLV) fell 3.1%. Is now the time to buy Solventum? Access our full analysis report here, it’s free.

• Surgical Equipment & Consumables - Specialty company LeMaitre (NASDAQ:LMAT) fell 3%. Is now the time to buy LeMaitre? Access our full analysis report here, it’s free.

• Drug Development Inputs & Services company UFP Technologies (NASDAQ:UFPT) fell 3.4%. Is now the time to buy UFP Technologies? Access our full analysis report here, it’s free.

• Medical Devices & Supplies - Cardiology, Neurology, Vascular company Artivion (NYSE:AORT) fell 3%. Is now the time to buy Artivion? Access our full analysis report here, it’s free.

Zooming In On UFP Technologies (UFPT)

UFP Technologies’s shares are very volatile and have had 22 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

UFP Technologies is down 1% since the beginning of the year, and at $243.73 per share, it is trading 32% below its 52-week high of $358.42 from September 2024. Investors who bought $1,000 worth of UFP Technologies’s shares 5 years ago would now be looking at an investment worth $5,398.

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.